| ²é¿´: 404 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
wxh7420238Òø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
Ìæ¿¼ÀÄþ¡¢Íò¹ÅÃ¹ËØÎÄÕ·Òë
|
|
|
1¡¢Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study 2¡¢Objectives: Higher vancomycin MIC values (¡Ý1.5 mg/L via Etest) may be associated with vancomycin treatment failure among patients with serious methicillin-resistant Staphylococcus aureus (MRSA) infections. 3¡¢Teicoplanin Etestw MICs and treatment outcomes for MRSA bacteraemia were reviewed to identify the breakpoint of teicoplanin MICs influencing treatment outcomes. 4¡¢A lower teicoplanin MIC was associated with a favourable outcome [37 (66.1%) versus 13 (28.9%); P,0.001] and a lower rate of bloodstream infection-related mortality [15 (26.8%) versus 22 (48.9%); P¼0.022]. 5¡¢ A higher teicoplanin MIC value (.1.5 mg/L) may predict an unfavourable outcome and highermortality rate among teicoplanin-treated MRSA bacteraemic patients. |
» ²ÂÄãϲ»¶
0855Çóµ÷¼Á²ÄÁÏ
ÒѾÓÐ12È˻ظ´
297·Ö083200ÇóÖú
ÒѾÓÐ7È˻ظ´
070300»¯Ñ§Ñ§Ë¶311·ÖÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
ר˶0854³õÊÔ¿¼²Ä¿Æ»ù£¬Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
0857´óÀà»·¾³¹¤³ÌBÇøÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
0817»¯Ñ§¹¤³ÌÓë¼¼ÊõÇóµ÷¼Á£¬Ò»Ö¾Ô¸Öк£Ñó319
ÒѾÓÐ14È˻ظ´
0703»¯Ñ§µ÷¼Á325·Ö
ÒѾÓÐ11È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£©
ÒѾÓÐ4È˻ظ´
Isaya_12
Òø³æ (³õÈëÎÄ̳)
- ·ÒëEPI: 14
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 351.6
- Ìû×Ó: 26
- ÔÚÏß: 16.9Сʱ
- ³æºÅ: 2462913
- ×¢²á: 2013-05-13
- רҵ: Ò©ÎïѧÆäËû¿ÆÑ§ÎÊÌâ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-05-28 21:53:44
wxh7420238: ½ð±Ò+25, ·ÒëEPI+1, ¡ï¡ï¡ïºÜÓаïÖú 2013-05-31 15:58:39
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-05-28 21:53:44
wxh7420238: ½ð±Ò+25, ·ÒëEPI+1, ¡ï¡ï¡ïºÜÓаïÖú 2013-05-31 15:58:39
|
1.Ìæ¿¼ÀÄþµÄ×îСÒÖ¾úŨ¶È¶Ô¸ÐȾÄͼ×ÑõÎ÷ÁÖ½ð»ÆÉ«ÆÏÌÑÇò¾úµÄ»¼ÕßȺÌåÖÎÁƽá¹ûµÄÓ°Ï죺һÏî»ùÓÚÒ½Ôº±³¾°µÄ»Ø¹ËÐÔÑо¿¡£ 2.Ä¿µÄ£º½Ï¸ßµÄÍò¹ÅÃ¹ËØÅ¨¶ÈÖµ(¡Ý1.5 mg / L£¬Í¨¹ýŨ¶ÈÌݶȷ¨ÊÔÑé)¿ÉÄܵ¼Ö¸ÐÈ¾ÖØÖ¢Äͼ×ÑõÎ÷ÁֵĽð»ÆÉ«ÆÏÌÑÇò¾ú£¨MRSA£©µÄ»¼ÕßȺµÄÖÎÁÆÊ§°Ü¡£ 3.¶ÔÌæ¿¼ÀÄþŨ¶ÈÌݶȷ¨²âµÃµÄ×îСÒÖ¾úŨ¶ÈºÍ¶ÔMRSAµÄÖÎÁƽá¹û½øÐÐÆÀ¹À£¬ÒÔÈ·¶¨Ì濼ÀÄþ×îСÒÖ¾úŨ¶ÈÓ°ÏìÖÎÁƽá¹ûµÄ¶Ïµã¡£ 4.½ÏµÍµÄÌæ¿¼ÀÄþ×îСÒÖ¾úŨ¶ÈÄܵõ½Ò»¸öÓÐÀûµÄ½á¹û[ʵÑé×é37 (66.1%) £¬¶ÔÕÕ×é13 (28.9%); P,0.001] £¬ºÍ¸üµÍµÄѪҺ¸ÐȾÖÂËÀÂÊ[ʵÑé×é15 (26.8%) £¬¶ÔÕÕ×é22 (48.9%); P¡¡.022]¡£ 5.½Ï¸ßµÄÌæ¿¼ÀÄþ×îСŨ¶ÈÖµ(.1.5 mg/L)¿ÉÄÜÔ¤ÆÚµÃµ½Ò»¸ö²»ÀûµÄ½á¹û£¬²¢µ¼Ö½ÓÊÜÁËÌæ¿¼ÀÄþÖÎÁƵÄMRSA¾úѪ֢»¼Õ߸ü¸ßµÄÖÂËÀÂÊ¡£ |
2Â¥2013-05-28 19:20:53














»Ø¸´´ËÂ¥